Market closed
Arrowhead Pharmaceuticals/$ARWR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Ticker
$ARWR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
609
Website
ARWR Metrics
BasicAdvanced
$2.5B
-
-$5.00
0.93
-
Price and volume
Market cap
$2.5B
Beta
0.93
52-week high
$36.72
52-week low
$17.05
Average daily volume
2.3M
Financial strength
Current ratio
6.741
Quick ratio
6.567
Long term debt to equity
442.561
Total debt to equity
445.881
Interest coverage (TTM)
-18.58%
Management effectiveness
Return on assets (TTM)
-39.43%
Return on equity (TTM)
-254.98%
Valuation
Price to revenue (TTM)
675.662
Price to book
13.43
Price to tangible book (TTM)
14.08
Price to free cash flow (TTM)
-3.97
Growth
Revenue change (TTM)
-98.53%
Earnings per share change (TTM)
160.27%
3-year revenue growth (CAGR)
-70.50%
3-year earnings per share growth (CAGR)
54.39%
What the Analysts think about ARWR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
ARWR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ARWR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
Business Wire·6 days ago
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Business Wire·2 weeks ago
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $2.5B as of January 29, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of January 29, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.